BioLife Solutions (NASDAQ:BLFS) Director Amy Duross Sells 477 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) Director Amy Duross sold 477 shares of BioLife Solutions stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $24.50, for a total value of $11,686.50. Following the completion of the sale, the director directly owned 30,210 shares of the company’s stock, valued at $740,145. This trade represents a 1.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Amy Duross also recently made the following trade(s):

• On Friday, November 21st, Amy Duross sold 1,000 shares of BioLife Solutions stock. The shares were sold at an average price of $26.00, for a total value of $26,000.00.
• On Thursday, November 20th, Amy Duross sold 4,523 shares of BioLife Solutions stock. The stock was sold at an average price of $24.51, for a total value of $110,858.73.

BioLife Solutions Stock Performance

BioLife Solutions stock traded up $2.33 during trading hours on Friday, reaching $26.53. 540,117 shares of the company’s stock traded hands, compared to its average volume of 456,202. BioLife Solutions, Inc. has a fifty-two week low of $19.10 and a fifty-two week high of $29.62. The firm’s 50 day moving average is $26.36 and its 200-day moving average is $24.10. The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of -221.06 and a beta of 1.97.

Institutional Investors Weigh In On BioLife Solutions

Hedge funds and other institutional investors have recently bought and sold shares of the company. CIBC Bancorp USA Inc. acquired a new position in BioLife Solutions during the 3rd quarter worth approximately $1,064,000. PharVision Advisers LLC acquired a new position in BioLife Solutions during the third quarter worth $316,000. Quarry LP grew its position in BioLife Solutions by 50.9% in the third quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock valued at $54,000 after purchasing an additional 713 shares in the last quarter. Millennium Management LLC increased its stake in BioLife Solutions by 2.9% in the 3rd quarter. Millennium Management LLC now owns 27,698 shares of the medical equipment provider’s stock valued at $707,000 after buying an additional 783 shares during the last quarter. Finally, Zacks Investment Management lifted its position in BioLife Solutions by 6.5% during the 3rd quarter. Zacks Investment Management now owns 69,230 shares of the medical equipment provider’s stock worth $1,766,000 after buying an additional 4,246 shares in the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on BLFS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a report on Wednesday, October 8th. Zacks Research upgraded BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research report on Friday, November 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $32.00 target price (up previously from $30.00) on shares of BioLife Solutions in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $31.20.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.